Shares of US biotech firm Ohr Pharmaceutical (Nasdaq: OHRP) plunged as much as 65% to $3.07 in heavy, premarket trade Friday, after the company said a Phase II study of its OHR-102 (0.2% squalamine lactate ophthalmic solution) combination therapy for the treatment for the wet form of age-related macular degeneration (wet-AMD) failed to meet its primary endpoint.
Ohr Pharmaceutical, an ophthalmology R&D company, today announced the top-line results from the exploratory Phase II IMPACT study evaluating OHR-102 combination therapy with blockbuster drug Lucentis (ranibizumab injection for the treatment of the wet-AMD.
Study results
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze